XML 18 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2017
Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ 81.1 $ (1.2)
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 13.2 9.2
Non-cash interest expense 0.1 0.1
Gain on disposition of assets (0.1) (0.2)
Share-based compensation expense 6.4 7.8
Bad debt expense 8.0 7.2
Deferred income taxes 4.7 3.2
Unrecognized tax benefits 6.7 0.4
Change in fair value of contingent consideration (73.2) 0.5
Changes in assets and liabilities:    
Prepaid expenses 3.2 7.8
Trade accounts receivable (16.5) (5.9)
Other receivables 0.3 (1.8)
Inventory 3.3 (13.0)
Prepaid taxes (8.9) (1.0)
Accounts payable 0.4 (5.0)
Accrued liabilities (5.8) (10.0)
Deferred revenue 0.6 (1.0)
Net cash provided by (used in) operating activities 23.5 (2.9)
CASH FLOWS FROM INVESTING ACTIVITIES    
Capital expenditures (1.6) (1.5)
Acquisitions, net of cash acquired   (213.0)
Purchases of marketable investment securities (31.5) (32.2)
Proceeds from maturities and sales of marketable investment securities 17.9 88.7
Net cash used in investing activities (15.2) (158.0)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from (payments for) common stock issued under share-based compensation plans 1.7 (1.9)
Net proceeds from issuance of debt   199.0
Repayment of revolving credit facility (25.0)  
Repurchase and retirement of common stock   (21.3)
Net cash provided by (used in) financing activities (23.3) 175.8
Effect of foreign exchange rates on cash and cash equivalents 0.5 3.5
Net increase (decrease) in cash and cash equivalents (14.5) 18.4
Cash and cash equivalents at beginning of the period 102.4 68.5
Cash and cash equivalents at end of the period $ 87.9 $ 86.9